このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Wave Life Sciences 配当金

配当金基準チェック /06

Wave Life Sciences配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.2%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$0.50
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Jun 25

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24

What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Aug 07

Wave Life Sciences posts proof-of-concept data from genetic disorder study

Jun 02

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

May 15

Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Apr 02

Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years

Feb 19

決済の安定と成長

配当データの取得

安定した配当: WVEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: WVEの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Wave Life Sciences 配当利回り対市場

WVE 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (WVE)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.8%
業界平均 (Pharmaceuticals)	2.2%
3年後のアナリスト予想 (WVE)	n/a

注目すべき配当: WVEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: WVEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: WVEの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: WVEが配当金を報告していないため、配当金の持続可能性を計算できません。

Wave Life Sciences 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Wave Life Sciences Ltd. Announces Positive Results from Phase 1b/2a Select-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Wave Life Sciences Ltd., Annual General Meeting, Aug 06, 2024

New major risk - Revenue and earnings growth

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Wave Life Sciences Ltd. to Report Q1, 2024 Results on May 09, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

CFO & Principal Accounting Officer notifies of intention to sell stock

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Wave Life Sciences Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Price target increased by 12% to US$9.21

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Price target increased by 14% to US$8.67

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Share price stability

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Consensus revenue estimates increase by 45%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Wave Life Sciences Ltd. to Report Q3, 2023 Results on Nov 09, 2023

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006

CFO & Principal Accounting Officer notifies of intention to sell stock

Consensus revenue estimates increase by 89%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Wave Life Sciences Ltd. to Report Q2, 2023 Results on Aug 03, 2023

Consensus revenue estimates increase by 12%

Wave Life Sciences Announces Topline Results from Phase 1B/2A Focus-C9 Study of WVE-004 for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Price target decreased by 10.0% to US$7.71

Consensus revenue estimates fall by 34%

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Consensus revenue estimates increase by 140%

President recently sold US$119k worth of stock

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Wave Life Sciences Provides Positive Update on Proof-Of-Concept Study for Wve-N531 in Duchenne Muscular Dystrophy

Price target increased to US$8.57

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Consensus forecasts updated

Insufficient new directors

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Insufficient new directors

Price target increased to US$9.33

Insufficient new directors

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Consensus revenue estimates fall by 21%

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Wave Life Sciences Ltd., Annual General Meeting, Aug 09, 2022

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from Russell 2000 Dynamic Index

Consensus forecasts updated

Price target increased to US$10.80

Wave Life Sciences Ltd. Announces First Clinical Data from Ongoing Focus-C9 Trial of Wve-004 for C9-Als and C9-Ftd

President notifies of intention to sell stock

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Wave Life Sciences Ltd. Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Wave Life Sciences Ltd. Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

President recently sold US$77k worth of stock

President notifies of intention to sell stock

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.86 loss in 3Q 2020)

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

配当金基準チェック /06